Coordinated Care Strategies for Psoriasis: An Organized Method for Timely Identification and Referral of Comorbid Conditions - Top-Institutions - MDSpire

Coordinated Care Strategies for Psoriasis: An Organized Method for Timely Identification and Referral of Comorbid Conditions

  • By

  • Anna López-Ferrer

  • Álvaro González-Cantero

  • Ana Gutiérrez-Casbas

  • Antonio Martorell

  • Antonio Olveira

  • María Blanca Madrid-Álvarez

  • Joana Nicolau

  • Jose Manuel Carrascosa

  • Ofelia Baniandrés

  • Raquel Rivera

  • Ricardo Ruiz-Villaverde

  • Rubén Queiro

  • Pablo de la Cueva

  • April 18, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    National Psoriasis Foundation
    National Psoriasis Foundation

    Portland, Oregon

    Key Differentiators

    • Dermatology
    • Rheumatology
    • Psychology
    • Gastroenterology

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Dermatology
    • Rheumatology
    • Gastroenterology
    • Endocrinology
    • Psychiatry

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, California

    Key Differentiators

    • Dermatology
    • Rheumatology
    • Gastroenterology
    • Psychiatry

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Dermatology
    • Rheumatology
    • Gastroenterology
    • Endocrinology

  • #5

    King’s College London, Dermatology Department
    King’s College London, Dermatology Department

    London, England

    Key Differentiators

    • Dermatology
    • Rheumatology
    • Gastroenterology
    • Psychiatry

Original Source(s)

Coordinated Care Strategies for Psoriasis: An Organized Method for Timely Identification and Referral of Comorbid Conditions

  • by Anna López-Ferrer, Álvaro González-Cantero, Ana Gutiérrez-Casbas, Antonio Martorell, Antonio Olveira, María Blanca Madrid-Álvarez, Joana Nicolau, Jose Manuel Carrascosa, Ofelia Baniandrés, Raquel Rivera, Ricardo Ruiz-Villaverde, Rubén Queiro, Pablo de la Cueva

  • April 18, 2026

Related Content

Bimekizumab in Psoriasis: 3-Year Outcomes

Investigators compare patient-reported symptoms and quality-of-life outcomes vs secukinumab.

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

Efficacy of Upadacitinib in Managing Coexisting Psoriasis and Lichen Planus: A Case Study